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Abstract
In the current study we undertook a series of experiments to test the hypothesis that a monogenic cause of disease may be
detectable within a cohort of Finnish young onset Parkinson’s disease patients. In the first instance we performed standard
genome wide association analyses, and subsequent risk profile analysis. In addition we performed a series of analyses that
involved testing measures of global relatedness within the cases compared to controls, searching for excess homozygosity
in the cases, and examining the cases for signs of excess local genomic relatedness using a sliding window approach. This
work suggested that the previously identified common, low risk alleles, and the risk models associated with these alleles,
were generalizable to the Finnish Parkinson’s disease population. However, we found no evidence that would suggest a
single common high penetrance mutation exists in this cohort of young onset patients.
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Introduction
Over the past 15 years the genetic investigation of Parkinson’s
disease has successfully identified many disease-causing mutations,
and these have been used extensively to understand the etiology of
this complex disease. Genome wide association (GWA) studies
have been applied to explicitly test the common disease common
variant hypothesis in PD [1]. This has led to the identification of a
significant number of novel risk loci [2–8]. From an etiologic
perspective it is notable that some of these loci include genes
known to contain mutations that cause neurodegenerative diseases
[9].
Within isolated populations, allelic and genetic heterogeneity
tends to be reduced and as a result single founder mutations can be
quite common in the disease population. Thus the application of
GWA in these populations can also lead to the resolution of loci
containing highly penetrant mutations, particularly in sub-types of
disease that have a substantial monogenic component within
conserved populations [10,11]. Perhaps the best example of this is
the description of association at chromosome 9p in a GWA of
familial ALS cases from Finland. This ultimately led to the
identification of the pathogenic expansion within C9orf72, which
causes a substantial number of ALS and frontotemporal dementia
cases worldwide [12,13].
We embarked upon a series of experiments aimed at
understanding whether a similar monogenic component may be
detectible in PD in the same population. To test this idea we used
high content SNP genotyping in a series of young-onset (,55 years
of age) Parkinson’s disease cases from Finland. This group was
used because the Finnish ancestry should reduce allelic and genetic
heterogeneity when compared to a more outbred population
[14,15], and because substantive evidence exists suggesting an
enrichment of monogenic disease in earlier onset PD [16].
Results
The primary dataset analyzed included genotype data on 387
PD patients with an age at first treatment of less than 55 years and
496 controls from the Vantaa 85+ Study. Standard GWA
procedures were instituted (see materials and methods) to identify
putative loci associated with young-onset PD, because age and
gender adjustments did not significantly affect overall results and
model fit, we opted to utilize the most parsimonious model,
excluding these covariates. Logistic regression models using non-
integer genotype dosages adjusting for component vectors one and
two from multi-dimensional scaling were tested. This was
performed across a total of 5,854,841 SNPs imputed based on
the 1000 Genomes Project haplotypes released in August 2009 (for
compatibility with previously published IPDGC studies) passing
quality control measures described below. No SNPs successfully
passed multiple test correction in the GWAS phase of analyses (p-
values ,5E-08, summarized in Figure 1).
Next we examined SNPs previously linked to PD risk [6,7]. Of
these 18 variants, 6 were genotyped successfully and another 7
were imputed with sufficient quality in the present study (note, due
to low coverage genotyping, 5 loci did not contain valid proxies
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that were successfully imputed at an r2.0.8). Although the current
study was not designed to detect common low risk variants, and
our effective power to do so was zero [17], it is notable that the size
and direction of effect for each of these variants is consistent with
the previous report (Table 1) [6].
Likewise, using these 13 variants, risk profile analysis revealed
an association between risk alleles previously defined in the
IPDGC meta-analysis and disease in this Finnish cohort. This was
performed using logistic regression to evaluate the effect of the
cumulative risk allele dosages, p = 2.0361028 [6]. The magnitude
of effects across risk quintiles was similar to those previously
observed, showing a .3 fold increase in risk of PD in the highest
versus lowest risk quintiles (Table 2).
Excess shared ancestry defined by identity by state (IBS) and
excess homozygosity analyses were also conducted to investigate
broader genetic associations within this dataset. Prior to conduct-
ing these analyses, all genotyped SNPs were pruned for linkage
disequilibrium using the methods described previously by us [18].
We did not find evidence for excess relatedness among cases
compared to controls either by IBS or an over burden of extended
tracts of homozygosity.
Sliding window functions were employed to estimate the local
rates of identity by state (IBS) differing between cases and controls;
these were analyzed in 500 kb sliding windows of the genome,
each overlapping by 250 kb. In this sliding window analysis, no
discrete genomic regions passed Bonferroni correction for
significance. This suggests that no loci were significantly over-
represented in the case-only IBS calculations compared to the
same analysis performed in controls. The threshold for significance
was set at a minimum unadjusted P,5E-06 based on approxi-
mately 10,580 sliding windows tested throughout the twenty-two
autosomes (,2645 MB).
Figure 1. Manhattan plot showing results of GWA testing between 378 PD cases and 496 controls from Finland, genomic inflation
factor =1.0659.
doi:10.1371/journal.pone.0041859.g001
Table 1. Results of association testing at published loci. OR published is based on replication phase odds ratio previously
published for these SNPs [6,7].
SNP
Minor
Allele ,
Major
Allele MAF IQ
Previously
published OR OR
Lower
95% CI
Upper
95% CI P-value Gene CHR BP
chr1:154105678 T,C 0.13 0.47 1.44 1.79 1.17 2.74 7.14E-03 SYT11 1 154105678
rs708723 C,T 0.40 0.99 0.86 0.93 0.77 1.13 4.81E-01 RAB7L1/PARK16 1 204005889
rs2102808 T,G 0.12 0.92 1.12 1.04 0.77 1.42 7.89E-01 STK39 2 168825271
rs34016896 T,C 0.33 1.00 1.08 1.10 0.90 1.35 3.71E-01 NMD3 3 162475558
rs11711441 A,G 0.12 0.99 0.87 0.80 0.58 1.09 1.47E-01 MCCC1/LAMP3 3 184303969
rs11724635 C,A 0.41 0.88 0.87 0.81 0.66 1.00 5.18E-02 BST1 4 15346199
rs6812193 T,C 0.33 1.00 0.91 0.86 0.69 1.06 1.48E-01 STBD1 4 77418010
rs356219 G,A 0.41 0.81 1.27 1.37 1.11 1.70 3.97E-03 SNCA 4 90856624
rs156429 C,T 0.37 0.98 0.89 0.83 0.67 1.02 7.50E-02 GPNMB 7 23272545
rs591323 A,G 0.33 0.83 0.88 1.01 0.81 1.26 9.25E-01 FGF20 8 16741462
chr8:89442157 T,C 0.03 0.63 1.29 1.04 0.52 2.08 9.13E-01 MMP16 8 89442157
rs1491942 G,C 0.14 1.00 1.30 1.14 0.85 1.54 3.67E-01 LRRK2 12 38907075
rs4889603 G,A 0.43 0.83 1.15 1.33 1.07 1.64 8.99E-03 STX1B 16 30889726
Note gene is the best proximal candidate or closest gene to the locus and may not be the true pathologically important species. Notably the power to detect
association at these loci, based on previously published effect sizes, p,5E-8, and an additive model is effectively 0 (based on methodology of [17]). MAF, Minor Allele
Frequency; OR, odds ratio; CI, confidence interval; IQ, Imputation quality from MACH (RSQR metric).
doi:10.1371/journal.pone.0041859.t001
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Homozygosity analysis was conducted based on overlapping
regions contained within runs of homozygosity using PLINK’s
inherent maxT permutation testing and empirical p-values were
corrected by label-swapping to exclude false positives per defined
region. No results exceeded the empirically determined threshold
for multiple test correction. Further, all samples were within the
relatively normal range of homozygosity, with a minimum Fhat of
2.012 and a maximum Fhat of 0.11 (calculated as previously
described [18]).
Discussion
In the current study we failed to identify an association signal
indicative of a shared, common mutation underlying younger
onset PD. Our sliding window analysis, aimed at identifying
genomic regions shared by cases more commonly than controls
also failed to identify any significant loci. Moreover our analyses
failed to reveal an excess of homozygosity in cases, thus failing to
support a role for a common recessive founder mutation in this
series; however, our study possessed fairly low power to detect less
frequent recessive mutations and thus we cannot exclude these as a
cause of PD in this cohort [18].
While these analyses suggest that there is not a predominant
single monogenic cause of disease in this group, we were able to
see evidence of genetic association within this cohort, consistent
with previous work in less conserved populations of European
descent [6]. The current work shows that the risk profiles
previously proposed by us in outbred populations of European
descent are generalizable to the Finnish population (Table 2).
Given the valuable nature of this cohort, we believe that further
investigation using methods designed to detect mutations in the
presence of genetic and allelic heterogeneity are warranted [9].
Materials and Methods
This research was conducted according to the principles
expressed in the Declaration of Helsinki. The Ethics Committee
of Turku University Hospital approved this study and all subjects
provided written informed consent.
In October 2007 all patients in Finland who had become
eligible for reimbursement for PD medication from 1995 to 2006,
who were ,55 years of age and who were alive on 1 October
2007, were identified from the Drug Reimbursement Register
(Social Insurance Institute of Finland database). In each case the
diagnosis fulfilled international criteria for PD. A nationwide
cohort of 1090 early-onset Parkinson’s disease (EOPD) patients
was identified. Following exclusion of children, recently deceased
and emigrants 1077 patients remained; study material was sent to
each of these subjects. In addition, the birthplace and age of each
of the parents were requested. Family history of PD and related
disorders (dementia, gait disorder and mental illness) were also
included in the questionnaire. A total of 460 (42.7%) participants
gave their acceptance for the study. All participants provided a
blood sample, completed questionnaire and informed consent. All
participants provided a blood sample, completed questionnaire
and informed consent. Four patients reported that their PD
diagnosis had been withdrawn and they were thus excluded from
the study. Seven patients were excluded, because their PD
diagnosis had been set at the age of 55 years. Altogether, 449
patients fulfilled the inclusion criteria. These participants recruited
as cases were genotyped using the Illumina Human660W version
1 BeadChip as per the manufacturers directions (Illumina Inc.,
CA).
Control samples were taken from the Vantaa85+ study
population. This control group comprises all persons aged 85
years or older who were living in the city of Vantaa on April 1,
1991. Of the 601 eligible subjects, peripheral blood (and DNA)
samples have been obtained from 515 study subjects. The
Vantaa85+ cohort was genotyped using Illumina HumanCNV370
BeadChips as per the manufacturers instructions (Illumina, Inc.,
CA). Basic quality control was undertaken including verification of
self-reported sex by examination of X chromosome heterogeneity
to estimate gender from genotype data and a minimum per sample
genome-wide call rate of 95% per sample in each of the two series.
Because of a failed genotyping run 56 of the attempted 447
samples failed our quality control metrics because of low genotype
rate. SNPs meeting the following criteria were excluded from the
case and control datasets prior to merging: ,95% genotyping
success rate per SNP, minor allele frequency (MAF) ,0.01,
Hardy-Weinberg equilibrium (HWE) p-value ,1E-4 in controls
and ,1E-7 in cases. After merging consensus genotyped SNPs
across both platforms, further quality control was undertaken
including filtering for missingness in cases compared to controls p-
value (from chi-squared test) ,1E-5 as well as nonrandom
missingness by haplotype (from chi-squared test) ,1E-5. The
case-control series was then merged with HapMap3 populations
and clustered using multidimensional scaling to verify northern
European ancestry consistent with self reported Finnish ancestry.
The case-control series then underwent the calculation of pairwise
identity by descent, excluding any samples sharing greater than a
0.15 proportion of alleles (pi_hat .0.15) to extract only probands
from related pairs, effectively excluding all first degree relatives.
An additional 4 samples were removed, 3 because of excess
relatedness and 1 because it was identified as a population outlier.
To generate covariates for logistic regression models, multidimen-
sional scaling was again used to quantify genetic distances between
remaining members of the case-control cohort.
Case and control data were trimmed to an overlapping set of
302,463 genotyped SNPs passing quality control measures
Table 2. Summary of risk-profile analysis in the Finnish, compared to the same risk profile analysis previously performed in a series
of European ancestry PD patients [6].
P value AUC Risk quintile: OR (95% CI)
First Second Third Fourth Fifth
IPDGC ,2610216 0.63 1.00 1.43
(1.27–1.62)
1.77
(1.55–1.99)
2.03
(1.80–2.32)
2.51
(2.23–2.83)
Finnish 2.03E-08 0.614 1.00 1.43
(0.92–2.22)
1.42
(0.91–2.20)
2.43
1.58–3.77)
3.02
(1.96–4.69)
AUC: area under the curve, indicated by the c index from receiver operator curves. OR: odds ratio.
doi:10.1371/journal.pone.0041859.t002
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described above. Imputation of genotypes was performed using a
Markov Chain based haplotyper (MACH; version 1.0.16) with
reference haplotypes derived from initial low coverage sequencing
of 112 European ancestry samples in the 1000 Genomes Project
(as of August, 2009) [19]. These data were imputed using a two-
stage design. The first stage generated error and crossover maps as
parameter estimates for imputation on a random subset of 200
samples over 100 iterations of the initial statistical model. We used
these parameter estimates to generate maximum likelihood
estimates of allele numbers per SNP on the basis of reference
haplotypes for the datasets during the second stage of the
imputation. SNPs with RSQR quality estimates of less than 0.30
as indicated by MACH and a minor allele frequency of less than
0.01 were excluded from analyses of the datasets, because imputed
genotypes below this threshold are likely poor quality.
We performed genome-wide dataset analyses at every site with
MACH2DAT [19]. We used non-integer allele numbers as a
primary predictor of Parkinson’s disease in logistic regression
models to account for imputation uncertainty as previously
described [6]. We used basic covariates of component vectors 1
and 2 from either principal components or multidimensional
scaling analyses of the case-control cohort to identify random
genomic differences between genotyped data from cases and
controls, which were used to adjust statistical models for covariates
accounting for possible population substructure.
The risk profile analysis was performed as previously described
[6,17,20]. Briefly, using alleles at 13 previously identified PD risk
loci, cumulative risk scores were assigned to each subject. These
were then ranked based on that score, and this ranked group then
divided into quintiles of risk. Risk associations per quintile were
then calculated with quintile 1 (lowest risk score) as the reference
group. Logistic regression models adjusting for component vectors
one and two from multidimensional scaling were used to quantify
risk per quintile using the lowest risk quintile group as a statistical
reference.
For IBD comparisons and the estimation of large runs of
homozygosity, linkage-pruned datasets of genotyped SNPs were
generated to avoid confounding by large blocks of highly
correlated SNPs. We excluded SNPs thought to be in high LD if
they met the criteria of variance inflation factor .1.05
(corresponding to a ,1% maximum multiple correlation coeffi-
cient with each sliding window) within any sliding window of 50
adjacent SNPs which scrolled through the genome at a rate of 5
overlapping SNPs per window for the autosomes, as sex
chromosomes were excluded from all analyses described in this
report. All IBS calculations were based on PLINKv1.07.
Based on this LD pruned data, PLINK was used to calculate
case and control specific rates of IBS (proportional allele sharing)
both genome-wide and within 500 kb sliding windows which
overlapped with adjacent windows by 250 kb. Permutation testing,
employing a fixed 10,000 permutations, was used to compare both
genome-wide and within window rates of identity by state among
cases and controls, testing the hypothesis that rates of IBS would
be higher among cases compared to controls.
Runs of homozygosity (ROHs) were defined using PLINK as
well, also based on the LD-pruned datasets. The criteria used for
defining a run of homozygosity included at least 1 MB of
consecutive homozygous calls per individual, containing at least
50 SNPs, and allowing only 2 missing SNPs and 1 heterozygote.
Total percent of the genome comprised of these runs was
calculated using the summed length of all of a participant’s ROHs
divided by the length of the autosomal genome. The frequency of
ROHs was defined as the total number of ROHs per individual.
Logistic regression adjusting for year of participant birth and
component vectors one and two from multidimensional scaling
was used to quantify risk for genome-wide burden of ROHs and
ROH frequency as predictors of PD.
Homozygosity mapping was undertaken using the previously
defined ROHs. Consensus regions were extracted from this set,
including loci that contained at least 3 SNPs across a minimum of
100 kb found in no less than three participants. A modified version
of the maxT permutation test implemented in PLINK to test for
copy-number variants was employed to assess the associations
between these consensus regions and PD in our study across
50,000 permutations.
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